30 Sep 2019 --- The US Food and Drug Administration (FDA) has issued guidance on how it will regulate “novel, swiftly evolving” digital health tools, such as mobile health software and products that use artificial intelligence (AI). The new guidelines include the assertion that lifestyle apps will be officially free of FDA oversight. Digital software for health is increasingly popular among both the public and health professionals and the FDA notes that its approach “must foster, not inhibit, innovation.”
